Plain-English translation of NCT06975865 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called can help reduce the painful episodes that people with sickle cell disease experience. Researchers want to see if this treatment can make these crises less frequent and severe, and whether it is safe to use. The study will last about one year and involve regular check-ins with the research team.
Sickle cell disease causes painful episodes that can seriously affect daily life, and current treatments don't work well enough for everyone. This trial exists to see if this medication offers a better option for managing these painful crises.
You likely qualify if…
You likely don't qualify if…
Over 52 weeks, you will take either the new medication or a placebo (a pill with no active ingredient) at home, and you won't know which one you're receiving. You will have regular visits with the research team to check your health, answer questions about pain episodes, and have blood tests or other assessments done. If the medication appears to be working, you may be invited to continue in an additional open-label phase where everyone receives the actual medication.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States